Pre-clinical human DCIS models further confirmed that combined Notch signaling inhibitor (DAPT) and Her2 inhibitors (lapatinib) could effectively inhibit DCIS acini growth and stem cell activity [43]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.